

Layer-by-Layer-Assembled Multilayer Films for Transcutaneous Drug and Vaccine Delivery

Xingfang Su,^{†,‡} Byeong-Su Kim,^{*,‡,‡,∇} Sara R. Kim,[‡] Paula T. Hammond,^{‡,§,*} and Darrell J. Irvine^{†,§,⊥,||,¶,*}

[†]Department of Material Science and Engineering, [‡]Department of Chemical Engineering, [§]Koch Institute for Integrative Cancer Research, [⊥]and Department of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, ^{||}Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts 02114, and [¶]Howard Hughes Medical Institute, 4000 Jones Bridge Road, Chevy Chase, Maryland 20815. ^{*}These authors contributed equally to this work.

[∇]Current address: School of Energy Engineering and School of NanoBio and Chemical Engineering, Ulsan National Institute of Science and Technology (UNIST), Korea.

Polyelectrolyte multilayers have attracted much interest for their versatility, ease of preparation, and ability to conformally coat virtually any substrate.^{1–6} Pioneering studies demonstrated that proteins could be assembled into such multilayers^{7,8} and retain their functionality,⁹ stimulating a broad interest in potential biomedical applications of these materials.^{3,10} Further, the ability of multilayers to be built from biocompatible and bioresorbable polyelectrolytes has led to additional applications, including modification of cell adhesion on surfaces,¹¹ tissue- and skin-bonding films,¹² coatings directly applied to epithelial or endothelial cell layers *in situ*,^{13,14} or even coatings on living single cells.^{15–17}

In concert with a growing interest in applying multilayers to biomedical applications, erodible multilayers that deconstruct in aqueous conditions *via* disassembly and/or breakdown of the constituent polymers have begun to be explored as potential controlled release drug delivery films.^{18–21} Drug-loaded degradable multilayers have been explored for the sustained release of small-molecule antibiotics, protein therapeutics, or plasmid DNA.^{3,7,18,19,21–24} The mild aqueous conditions for encapsulating molecules into multilayer films preserve the bioactivity of fragile biomolecules such as proteins and nucleic acids.^{21,22,25} By employing degradable polyelectrolytes as building blocks, the ability to tune the degradation kinetics of multilayer assemblies has been demonstrated and used to control the release kinetics of compounds embedded in these films.^{20,26} Applications envisioned for such drug-loaded films include antimicrobial or

ABSTRACT We describe protein- and oligonucleotide-loaded layer-by-layer (LbL)-assembled multilayer films incorporating a hydrolytically degradable polymer for transcutaneous drug or vaccine delivery. Films were constructed based on electrostatic interactions between a cationic poly(β -amino ester) (denoted Poly-1) with a model protein antigen, ovalbumin (ova), and/or immunostimulatory CpG (cytosine—phosphate diester—guanine-rich) DNA oligonucleotide adjuvant molecules. Linear growth of nanoscale Poly-1/ova bilayers was observed. Dried ova protein-loaded films rapidly deconstructed when rehydrated in saline solutions, releasing ova as nonaggregated/nondegraded protein, suggesting that the structure of biomolecules integrated into these multilayer films is preserved during release. Using confocal fluorescence microscopy and an *in vivo* murine ear skin model, we demonstrated delivery of ova from LbL films into barrier-disrupted skin, uptake of the protein by skin-resident antigen-presenting cells (Langerhans cells), and transport of the antigen to the skin-draining lymph nodes. Dual incorporation of ova and CpG oligonucleotides into the nanolayers of LbL films enabled dual release of the antigen and adjuvant with distinct kinetics for each component; ova was rapidly released, while CpG was released in a relatively sustained manner. Applied as skin patches, these films delivered ova and CpG to Langerhans cells in the skin. To our knowledge, this is the first demonstration of LbL films applied for the delivery of biomolecules into skin. This approach provides a new route for storage of vaccines and other immunotherapeutics in a solid-state thin film for subsequent delivery into the immunologically rich milieu of the skin.

KEYWORDS: layer-by-layer · transcutaneous delivery · vaccine · polymer assembly · biodegradable

anti-inflammatory coatings on implants and drug-releasing coatings for stents.^{24,27,28}

Given the ability of multilayers to be conformally coated on a broad range of substrates to load both small-molecule and macromolecular drugs and to regulate the release of drugs over a period of hours to days, we became interested in the potential of these polyelectrolyte films in a new application area: transcutaneous drug delivery. Skin is an attractive site for noninvasive delivery of therapeutics, due to the ease of access to this organ and the ability of transcutaneous delivery to limit first-pass drug metabolism and alter the pharmacokinetics and pharmacodynamics of drugs.^{29,30} Epicutaneous immunization, the

See the accompanying Perspective by Voegel on p 3343.

*Address correspondence to hammond@mit.edu, djirvine@mit.edu.

Received for review August 3, 2009 and accepted October 5, 2009.

Published online October 13, 2009. 10.1021/nn900928u CCC: \$40.75

© 2009 American Chemical Society

topical delivery of vaccine antigens into the epidermis or dermis of skin, offers the advantages of needle-free delivery while targeting an immune sentry-rich natural portal of pathogen entry.^{31–33} We hypothesized that drug-loaded multilayers coated on the surface of a skin-adhesive patch or wound dressing could provide several attractive features for transcutaneous drug delivery: (i) interactions of embedded proteins with the multilayer components might stabilize proteins against aggregation on drying, facilitating storage of protein therapeutics in a dry state; (ii) the concentration of a substantial cargo of drug into an ultrathin coating directly apposed to the surface of the skin would provide a strong diffusive driving force promoting penetration of drug cargos into the skin; (iii) multilayers could be designed to release multiple components and separately regulate the kinetics of release of individual drug components to optimize a therapeutic response; and (iv) the versatility of multilayer assembly would allow this concept to be implemented in a variety of transcutaneous delivery settings, including coatings of simple skin-adhesive patches, woven-fiber adhesive dressings, or microneedle arrays.

Here we report on studies testing each aspect of this hypothesis, in a model setting of protein- and DNA-loaded multilayer thin films coated on model skin patch substrates. We demonstrate that biodegradable multilayers can be loaded with a model protein antigen at doses physiologically relevant to vaccination, that dried multilayers release the embedded protein in a monomeric, unaggregated form on rehydration and erosion of the films, and that model patch substrates coated with multilayers and applied to tape-stripped skin (a simple procedure often used to permeabilize the outer layers of the stratum corneum in transcutaneous vaccination studies^{34–36}) rehydrate and dissolve *in situ*, releasing protein into the epidermis. Using a transgenic mouse model where epidermal antigen presenting cells (Langerhans cells) express green fluorescent protein (GFP)-tagged major histocompatibility complex molecules, we demonstrate that protein antigen released from multilayer patches is acquired by these immune cells in the skin within hours of application of the film. Finally, we demonstrate the incorporation of multiple drug cargos in films, illustrated for the case of vaccine design by embedding a protein antigen together with an adjuvant molecule, single-stranded CpG DNA oligonucleotides. We show that antigen and adjuvant can be loaded together in decomposable multilayer coatings and released with distinct kinetics, as may be desirable for temporally controlling the induction of an immune response (or other therapeutic response). Using the murine skin model, we show that both vaccine components can be delivered to Langerhans cells in the epidermis from skin-applied multilayer films.

RESULTS AND DISCUSSION

To fabricate a PEM film capable of releasing macromolecular cargos into skin, we utilized polyelectrolytes belonging to the family of poly(β -amino esters), known to degrade hydrolytically under physiological conditions, focusing on two members of this family designated Poly-1 and Poly-2 (Figure 1 and Supporting Information, Figure S1).³⁷ The biocompatibility of Poly-1 has been established in earlier studies, and we have previously employed this polymer to fabricate LbL films with controlled erosion and tunable drug release profiles.^{19,22,38} As a model protein cargo, we examined the assembly of multilayers containing ovalbumin (ova), a 45 kDa globular protein routinely used as a model vaccine antigen.^{39–41}

We first prepared PEM films by alternating adsorption of Poly-1 and ova from aqueous buffers onto glass slides, utilizing electrostatic interactions between the protein and polymer to mediate assembly and monitoring protein incorporation *via* the absorbance of fluorophore-conjugated ova. On the basis of the pI of ova (\sim 4.6) and the pK_a of Poly-1 (between 4.5 and 8), we tested film assembly at pH 5–7, varying the pH of both Poly-1 and ova adsorption solutions (Figure S2 in Supporting Information).³⁷ As summarized in Figure 1b, film growth was approximately linear for deposition buffer pH values of 5/6 and 6/6 for Poly-1/ova bilayers. Maximal incorporation of ova was achieved by adsorbing both Poly-1 and ova at pH 6. For ova adsorption buffers at pH > 6, loading decreased, possibly due to decreasing charge density of Poly-1, which contains tertiary amine groups, at higher pH.¹⁹ Measurement of the total amount of ova released from completely dissolved films showed that, for films assembled at pH 6, 40 bilayer films carried 5 $\mu\text{g}/\text{cm}^2$ ova protein total (40 bilayer films are *ca.* 150 nm). In the context of vaccination, this order of dose/area is well within a meaningful range as antibody responses have been reported for transcutaneous antigen doses as low as 3 μg .^{42–44}

When dried as-assembled (Poly-1/ova)_n PEM films on glass were rehydrated in phosphate-buffered saline (PBS, pH 7.4), films prepared across all deposition conditions exhibited rapid protein release, as illustrated in Figure 1c. Characterization of (Poly-1/ova)₄₀ film thickness *versus* time following rehydration revealed rapid dissolution of the films coinciding with protein release. These films fall apart significantly more rapidly than others assembled with other proteins or biopolymers^{19,21} and also greatly exceed the rate of polyaminoester hydrolysis anticipated for Poly 1. For this reason, we believe that ova, which is a relatively small and globular protein with low surface charge density, is able to readily diffuse out of the Poly 1 films upon contact with aqueous solution, leading to a charge destabilization of the electrostatically assembled thin film and subsequent rapid dissolution of the film. Though the pH/ionic strength conditions used for PEM




Figure 1. (a) Schematic illustration of the events taking place following the application of PEM patch onto skin. (1) PEM patch on a substrate is applied onto tape-stripped ear skin. (2) Ova is released from the patch as the multilayer disassembles, and ova then penetrates to reach the LCs located at the basal layer of the epidermis. (b) Growth curve of (Poly-1/ova) multilayers for two different deposition conditions, as assessed by absorbance from fluorophore-conjugated ova incorporated in films. (c) Cumulative normalized kinetics of ova release from LBL films rehydrated in PBS (pH 7.4 at 25 °C), for films prepared with Poly-1 vs Poly-2 and for Poly-1 deposition at low or high ionic strength. Representative thickness changes with time for a Poly-1/ova film assembled at high ionic strength. (d) Photograph of (Poly-1/ova-Texas Red)₄₀ film assembled on a flexible PDMS substrate. (e) Native PAGE analysis of ova released from (Poly-1/ova)₄₀ films after a 30 min rehydration in PBS, for films prepared by depositing ova at a fixed pH 6 and Poly-1 at pH 5.5, 6, or 6.5, respectively. Protein released from films is compared to controls of ova solutions in PBS pH 7.4 or in the multilayer deposition solution (pH 6, 100 mM NaOAc buffer).

assembly here are near the buffer conditions used for analysis of rehydration and disassembly, our previous studies based on multilayer complexes of Poly-1 and anionic polysaccharides illustrated that subtle changes in solution pH can have dramatic effects on film disassembly kinetics.¹⁹ The overall release kinetics were modestly altered either by using the more hydrophobic poly(β -amino ester) (Poly-2) for film assembly or by decreasing the ionic strength of the dipping solutions from 100 to 10 mM to reduce charge screening and increase electrostatic interactions between the polyions during assembly, resulting in more tightly associated PEM films (Figure 1c). Although there are undoubtedly additional strategies that could be used to further regu-

late protein release from these films, for our initial studies, we hypothesized that rapid film dissociation on rehydration could be potentially advantageous for allowing maximal delivery of antigen/adjuvant molecules into barrier-disrupted skin prior to sealing of the epidermis (discussed further below).

These basic characterization measurements were made for films on glass substrates, which may not be ideal for application on skin. However, as there is virtually no restriction in the choice of the substrate for LbL assembly, we next tested assembly of Poly-1/ova films on substrates that might be useful in skin patch formulation. We tested poly(dimethylsiloxane) (PDMS) as an elastomeric substrate that could form the basis of eas-

ily handled macroscopic patches, exploiting its well-known utility in microcontact printing to achieve intimate contact between drug-loaded multilayers and the inhomogeneous surface structure of skin. As illustrated in Figure 1d, film assembly was readily achieved on flexible PDMS substrates, and incorporation of fluorescent ova (ova-Texas Red) was readily observed from the blue hue of multilayer films on the transparent rubber.

We next tested whether ova protein assembled into Poly-1 LbL films, dried, and then rehydrated and released into buffer remained intact and unaggregated by running both nonreducing SDS–PAGE (Figure S3 in Supporting Information) and native PAGE on supernatants taken from (Poly-1/ova)₄₀ films assembled at different pH values, dried, and then rehydrated in PBS for 30 min. As seen in Figure 1e, almost all of the ova released from Poly-1 films existed as monomeric protein running at the same position as unmanipulated control ova solutions in PAGE gels, indicating that the structural integrity of ova was preserved during both integration into and subsequent release out of the films. Ova released from films did not show significant signs of aggregation either with itself or with released Poly-1, as indicated by the lack of protein detected at positions above the main band of free ova in the PAGE gels. Lack of aggregation or degradation in the released ova suggests that proteins can be incorporated into Poly-1 LbL films, dried, and released in a native monomeric state on rehydration without irreversible complexation to the polycation component of the films, an important outcome for the bioactivity of therapeutics or for the correct elicitation of antibody responses for vaccine antigens.

To assess antigen penetration into skin from LbL multilayers, we employed a murine ear skin model often used for analysis of antigen delivery for epicutaneous vaccination.^{45,46} This site provides a clearly defined draining lymph node (the auricular node) for immunological analysis, and Langerhans cells (LCs) within the ear are readily visualized by microscopy, allowing direct observation of protein delivery to these dendritic cells in intact tissue. Importantly, despite differences between murine and human skin structure, murine studies have been remarkably predictive for human clinical trials.³² In order for vaccine agents to reach viable immune cells in the epidermis or dermis, the stratum corneum (SC), the thin, nonliving, exterior lipid-rich barrier layer of the skin, must be bypassed.⁴⁷ One approach to transcutaneous vaccination is to employ adjuvant compounds that disrupt the integrity of the SC, such as cholera toxin derivatives or heat-labile enterotoxin from bacteria.^{42,43} A simple and safe alternative is to physically disrupt the SC. This can be achieved using an approach such as glue or tape-stripping, based on the repeated application and removal of adhesives on skin, a process shown to remove the outer 10–20 μm of the SC. This barrier disruption process is painless, highly ef-

fective in augmenting the transfer of macromolecules such as proteins or DNA into skin, and has been successfully utilized in human clinical trials.^{46,48–50} An additional advantage is that physical barrier disruption itself has been shown to trigger activation of keratinocytes and LCs in skin, providing some level of “built-in” adjuvant response.^{44–46,49–52} We thus tested a model where the dorsal ears of anesthetized mice were tape-stripped followed by application of as-assembled, air-dried (Poly-1/ova)₄₀ films on either glass or PDMS substrates, fixed in place by surgical tape against the exposed ear skin, mimicking a common strategy used in skin vaccination studies^{45,46} (Figure 1a). Tape-stripping reproducibly removed significant portions of the SC but did not disrupt the viable epidermis, as assessed by histology (Figure S3 in Supporting Information).

To assess protein release from LbL films into tape-stripped skin, films carrying fluorescent ova were assembled on PDMS patch substrates and applied to tape-stripped ear skin of C57Bl/6 mice or transgenic MHC II-GFP mice, whose Langerhans cells express GFP-tagged MHC molecules and are thus intrinsically labeled in the tissue. For comparison, we applied gauze pads loaded with an equivalent amount of fluorescent ova in saline to tape-stripped skin, mimicking the approach typically taken in vaccine studies. Mice were euthanized 48 h later, the PDMS patch or gauze was removed, and the skin sites were examined by confocal microscopy. Optical sections revealed the penetration of ova released from LbL films into the epidermis down to depths where LCs reside, 10–15 μm below the surface of tape-stripped skin (Figure 2a,b; LCs are readily distinguished by their branched/dendritic morphology). In separate experiments using C57Bl/6 mice, LCs deep in the epidermis below the main front of skin-penetrating ova were observed with pockets of internalized ova (Figure 2c), indicating that the cells were able to take up the delivered protein antigen from their surroundings. At the 48 h time point, LCs were observed with less pronounced dendritic morphology and at deeper depths than seen in fresh skin explants, suggesting that the cells were activated and in the process of beginning their slow migration to lymph nodes—a process known to occur over a few days.^{53,54} In contrast, ova solutions applied to tape-stripped skin showed much less protein accumulation in the skin, and LCs were present at depths and densities in the epidermis more reminiscent of untreated skin (Figure 2b).

Immune responses are initiated in lymph nodes, where antigen-bearing dendritic cells directly interact with T- and B-lymphocytes, and thus antigen delivery to the nodes is critical for primary immune responses. Transport of antigens from the skin to the local lymph nodes can occur through direct draining of antigen deposited into the skin *via* lymphatic vessels or by cell-mediated transport, where activated LCs or other dendritic cells internalizing antigen in




Figure 2. (a) Overlay confocal micrographs (upper panel) taken at 5 μm intervals showing the penetration of Texas Red-conjugated ova (red) released from LbL films into tape-stripped ear skin of a MHC II-GFP mouse following application of a Poly-1/ova PDMS patch for 48 h. Corresponding GFP fluorescence confocal micrographs (lower panel) showing Langerhans cells (LCs, green) appearing at z depths of 10–15 μm below the tape-stripped skin surface, just above the epidermis–dermis boundary. (b) Representative vertical cross sections and quantitative plots of fluorescence intensity normalized to maximum values for ova (red) and LC fluorescence (green) in skin treated with ova-loaded LbL films (filled symbols) or gauze pads with ova solution (open symbols). (c) Micrograph from an independent experiment, demonstrating colocalization of Alexa Fluor 488-conjugated ova (green) released from a Poly-1 LbL film and immunostained LCs (red) in the skin of a C57bl/6 mouse observed at a deeper depth where free ova in the surroundings is no longer detected, suggesting that activated LCs have taken up penetrated antigen and begun migration to lymph nodes. All scale bars are 20 μm .

the skin migrate to the lymph nodes. To determine whether protein antigen released from LbL films applied to skin was transported to draining lymph nodes, murine ears were tape-stripped and LbL films on glass substrates carrying Alexa Fluor-conjugated ova were applied to the skin using surgical tape. As before, we compared LbL films to skin treated with gauze loaded with an equivalent amount of ova in saline. After 48 h, the skin-draining auricular lymph nodes were excised, digested, and recovered leukocytes were stained with antibodies for flow cytometry analysis. At this time point, ova fluorescence could be directly visualized within intact lymph node tissue at low magnification (Figure 3a). CD11c is generally regarded as a marker for dendritic cells, while CD11b is used to mark cells of myeloid lineage in-

cluding monocytes and macrophages. Murine LCs and other dendritic cells migrating from skin have been shown to express both CD11c and CD11b surface molecules.^{55,56} As illustrated in Figure 3b,c, protein transport to the lymph nodes was detected following treatment with a (Poly-1/ova)₅₀ LbL patch when examining both the total lymph node cell population as well as individual cell subsets. Though CD11c⁺CD11b⁺ dendritic cells make up only a few percent of the total lymph node cells (e.g., as shown in the CD11c vs CD11b flow cytometry plot for ova⁻ cells), these cells were greatly preferentially enriched in the ova⁺ cell population, with ~64% of ova⁺ cells being of the CD11c⁺CD11b⁺ subset (Figure 3b). As shown in Figure 3c, ~14% of all CD11c⁺CD11b⁺ dendritic cells acquired fluorescent ova following LbL




Figure 3. (a) Confocal micrograph of intact auricular lymph node draining the ear site where ova-loaded LbL film was applied, showing ova fluorescence (green) accumulated in the tissue (scale bar = 20 μm). (b) Left panels: Flow cytometry plots showing the proportion of total lymph node cells carrying ova (percentages quoted quadrant corners) as detected in the draining lymph node following skin treatment with ova-loaded LbL films or PBS as a control for 48 h. Right panels: Plots of CD11b vs CD11c for ova⁺ (green quadrant) and ova⁻ (red quadrant) cells from the lymph nodes of mice treated with ova-loaded LbL films, showing that the majority of ova-bearing cells were CD11b⁺CD11c⁺ Langerhans cells and dendritic cells. (c) Percentages of ova⁺ cells detected in macrophage and dendritic cell population subsets of skin-draining lymph nodes determined by staining recovered leukocytes for CD11c and CD11b surface markers. (d) Flow cytometry histograms of surface expression of co-stimulatory molecules CD40, CD86, and MHC II by ova⁺CD11c⁺ dendritic cells (green line) and ova⁻CD11c⁺ dendritic cells (red line) recovered from lymph nodes of mice treated with ova-loaded LbL films.

film release of ova into the skin. Compared to tape-stripped skin treated with ova solution, ~ 1.8 -fold more DCs and 2-fold more macrophages were positive for ova in the draining lymph nodes following LbL film delivery of the protein. Ova⁺CD11c⁺ dendritic cells exhibited up-regulation of the cell-surface activation markers CD40, CD86, and MHC II compared to ova⁻ dendritic cells (Figure 3d), suggesting that antigen-bearing DCs originating from skin acquired a mature phenotype during migration to the draining lymph nodes, consistent with prior studies.^{57,58} Mature dendritic cells are poised to present antigen and provide the appropriate stimulation required to trigger T- and B-cell activation. Thus, protein antigen released into barrier-disrupted skin from LbL films is delivered to skin-draining

lymph nodes, where it accumulates in mature dendritic cells.

An attractive property of multilayers for controlled drug release is the ability to load multiple components into multilayer films and potentially tune the release kinetics of these cargos separately *via* the architecture of the films.¹⁹ To explore multicomponent drug delivery in the context of a transcutaneous vaccine, we next assembled LbL films incorporating both a protein antigen and an adjuvant cargo. Adjuvants are compounds typically co-injected with vaccines to increase their potency, reduce the required antigen dosage for a protective response, and/or elicit immune memory with an appropriate protective profile.⁵⁹ We tested the co-incorporation of ova antigen in LbL films with CpG DNAs, short single-stranded oligonucleotides that con-




Figure 4. (a) Schematic architectures of antigen (ova) and adjuvant (CpG DNA) co-delivery films tested. (b) AFM surface morphology of the corresponding dried films ($10 \times 10 \mu\text{m}^2$ images, z scale of 200 nm). (c) Kinetics of ova and CpG release from dried LbL films rehydrated in PBS (pH 7.4, 25 °C). Released ova and CpG were measured by collecting non-overlapping fluorescence signals ($\lambda_{\text{max,Ova}} = 665$ nm, $\lambda_{\text{max,CpG}} = 560$ nm, respectively). Overlay of normalized ova and CpG release curves from film architecture B.

tain unmethylated CpG (cytosine–phosphate diester–guanine) sequences characteristic of bacterial DNA. CpG DNA oligos are ligands for Toll-like receptor-9 on dendritic cells and other innate immune cells and are a potent adjuvant currently in clinical trials for a variety of vaccine and cancer immunotherapy applications.⁶⁰ Immunologically, adjuvant signals such as CpG trigger dendritic cell activation, which is accompanied by a down-regulation of antigen internalization by these cells.⁶¹ Thus, we hypothesized that, for vaccination, films capable of releasing antigen coincident with or prior to adjuvant release would be attractive. Further, sustained adjuvant delivery (mediated in basic immunological studies by repeated injections) has been shown to help break tolerance to tumor antigens in the setting of cancer vaccines, and so the ability to release adjuvant molecules for a period of several days could be a second important opportunity for LbL vaccine films.⁶²

To regulate the release of antigen and adjuvant in composite films containing ova and CpG, we explored different sequences of layering in order to determine the impact of film architecture on the loading and release kinetics for the two components. We were also interested in examining potential interactions between ova and CpG within the film structure. Using Poly-2 as a complementary polycation for the two polyanionic cargos, co-delivery films containing ova and CpG were constructed with several different architectures (Figure 4a): control films of ova (A) or CpG (E) alone with Poly-2,

CpG layered on top of ova (B), alternating ova and CpG (C), or ova layered over CpG (D). In each case, 20 bilayers of Poly-2/ova and Poly-2/CpG were included. AFM imaging of dried films (Figure 4b) showed that each film composition exhibits a distinct surface morphology: films containing ova were generally rougher than CpG-loaded films (mean rms roughness 31 ± 3 nm for (Poly-2/ova)₂₀ films vs 8.5 ± 2 nm for (Poly-2/CpG)₂₀ films). As described earlier, the release characteristics of the ova films suggest a high degree of interdiffusion of ova within the film and high concentrations of ova at the top surface, typical of interdiffusion growth behavior.⁶³ The roughness of the surfaces of the ova films may be a result of this interdiffusion and accumulation of ova protein in the top layers. Film structures A and D, which were both terminated with multiple Poly-2/ova bilayers, were quite similar in their rough surface topography, whereas film structures B and C were rougher than E (pure Poly-2/CpG) films even though each film terminated with a Poly-2/CpG bilayer. These results suggest the presence of ova near the surface in some substantial concentration in each of these two film architectures, as well, and thus indicate the potential for interdiffusion of the adsorbing species during assembly. We postulate that ova is a more diffusive species within the LbL layers compared to the more densely charged CpG oligonucleotides, despite its larger molecular weight. It has been shown that charge density is a key controlling element in the ability of macromolecular species to diffuse within multilayer films.^{20,64,65} The CpG-




Figure 5. (a) Overlay confocal micrographs (top and middle panels) taken at $5\ \mu\text{m}$ z intervals (z depth indicated in upper left of each image) showing the penetration of fluorophore-conjugated ova (red) and CpG (blue) released from LbL films (architecture B from Figure 4a) into tape-stripped ear skin of MHC II-GFP mouse following patch application for 48 h. Corresponding GFP fluorescence confocal micrographs (bottom panel) showing LCs (green). (b) Representative horizontal (left) and vertical (lower right) cross sections showing colocalization of fluorescent ova and CpG with GFP⁺ Langerhans cells (indicated by white arrows; inset figure shows individual fluorescent channel images of boxed region), suggesting uptake of penetrated antigen and adjuvant by the dendritic cells. Similar results were also observed for film architecture C (data not shown). Depths (below tape-stripped skin surface) of x - y confocal optical slices are noted (in μm) in upper left of micrographs. All scale bars are $20\ \mu\text{m}$.

only films illustrate a more linear release over much more extended time frames that correspond well with surface hydrolysis of the multilayer films. This hypothesis is further supported by the release profiles collected in Figure 4c, showing rapid release of ova from films rehydrated in PBS for all film architectures, similar to the results observed for pure Poly-1/ova films. In contrast, a sustained release of CpG adjuvant over 3 days is observed in all cases. Although each film architecture was prepared with the same number of bilayers of ova or CpG, the total amount of each component within the final films varied significantly with film architecture. In earlier work, we found that if an underlying multilayer system exhibits a high degree of interdiffusion during its construction, then a second set of multilayers assembled atop the first will often also exhibit interdiffu-

sion into the pre-existing film;¹⁹ this behavior provides opportunity for high loadings of both components *via* diffusion and trapping of excess molecules within the film. Notably, architecture “B” with ova deposited first under bilayers containing CpG enabled the loading of large quantities of both components in the film and exhibited attractive staggered release kinetics, with the majority of antigen rapidly released within 24 h, while the CpG adjuvant exhibited sustained release over a period of ~ 3 days. Although further tuning of component loading and individual release kinetics can be readily envisioned by manipulation of film assembly conditions and the choice of polycation components, the staggered release of antigen and adjuvant presented here demonstrates the potential of this approach to vaccine and other drug cargo delivery.

Finally, we tested the ability of ova/CpG composite films coated on PDMS “patches” to deliver both antigen and adjuvant into tape-stripped murine ear skin. Similar to the experiments with Poly-1/ova films, multilayer-coated PDMS patches loaded with fluorescently tagged ova and CpG (architecture B) were applied to ear skin of MHC II-GFP mice for 48 h, then patches were removed and the skin sites were analyzed by confocal microscopy. Optical sections tracked the penetration of both labeled ova and CpG released from the film into the epidermis of tape-stripped skin down to 15 – $20\ \mu\text{m}$ below the tape-stripped surface (Figure 5a). Colocalization of GFP⁺ LCs with ova and CpG fluorescence (Figure 5b) was likewise observed, suggesting LCs internalized both penetrated antigen and adjuvant from their surroundings. Interestingly, at the 48 h time point LCs were detected at greater depths of

15 – $20\ \mu\text{m}$ compared with films containing only ova, possibly reflecting the effect of CpG activating LCs and enhancing their migration toward lymphatics located deeper in the skin *en route* to regional lymph nodes. Similar results were observed for films with architecture C. Thus, erodible ultrathin films loaded with antigen and adjuvant compounds can deliver both components into skin, providing delivery to dendritic cells in the skin as required for the initiation of immune responses. Analysis of the immune response triggered by such multilayer-coated patches is currently underway and will be presented in due course.

CONCLUSIONS

In summary, we demonstrated here protein-loaded LbL-assembled films as platform materials for construct-

ing skin vaccine or drug delivery patches. This study provides a proof-of-principle for the use of dry LbL films as skin vaccine patches, whereby films loaded are rehydrated *in situ* on barrier-disrupted skin, antigen and adjuvant are released into the epidermis where they are taken up by skin-resident dendritic cells, and antigen is transported to draining lymph nodes. The ability of multilayer films to incorporate protein that can be stored in a dry state prior to application and then released from rehydrated films in a nonaggregated/non-degraded state may allow extended storage/shelf life of vaccine formulations and address challenges in vaccine distribution in developing countries. The generality of LbL assembly suggests that a variety

of antigen and adjuvant molecules should be readily incorporated into these films. In addition, the ability of multilayers to conformally coat substrates should allow this approach to be used in tandem with other techniques for breaching the stratum corneum, such as using microneedles coated with multilayer delivery films.¹⁹ To make this platform truly generic for delivering a wide range of synthetic antigens and adjuvants, biodegradable nanocarriers might be embedded as delivery vehicles within LbL films to segregate film assembly/release properties from the characteristics of individual antigens/adjuvant molecules—an examination of such strategies is the subject of ongoing studies.

METHODS

Materials. Poly(β -amino esters) were synthesized according to previous literature.⁹ Alexa Fluor 488, Alexa Fluor 647, and Texas Red-conjugated ovalbumin, NuPAGE 10% Bis-Tris gels, 10% Tris-glycine gels, and all PAGE reagents were purchased from Invitrogen (Eugene, OR). All antibodies, antimouse PE-I-A^b, antimouse APC-CD11c, antimouse PE-CD11b, antimouse PE-CD40, and antimouse PE-CD86 were purchased from BD Biosciences (San Jose, CA). CpG oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA).

Film Preparation. All LbL films were assembled with a modified programmable Carl Zeiss HMS DS50 slide stainer. Typically, films were constructed on a glass slide with approximate size of 1×2 in², which was treated in a plasma cleaner (Harrick Scientific Corp.) with O₂ plasma for 5 min prior to use. The substrate was then dipped into Poly-1 solution (2.0 mg/mL in 100 mM NaOAc buffer) for 10 min and followed by three sequential rinsing steps with pH-adjusted water for 1 min each. Then the substrate is dipped into ova solution (0.10 mg/mL in 100 mM NaOAc buffer) for 10 min and exposed to the same rinsing steps as described above. The PDMS substrate was initially coated with poly(allylamine hydrochloride) (50 mM, pH 7.5), followed by the same protocol to build (Poly-1/ova)_n multilayer as described above. Co-delivery film of ova with CpG was constructed in a similar manner with CpG solution (0.10 mg/mL in 100 mM NaOAc buffer, pH 6, mixture of 10% TAMRA-labeled DNA).

Film Characterization. Protein loading on the film was quantified by measuring the absorbance of protein within the film using a UV/vis spectrophotometer (Varian Cary 600). Ova and CpG release from the film was followed by measuring the fluorescence spectra of released ova-AF 488, ova-AF 647, and TAMRA-CpG in PBS (Quantamaster Fluorimeter, PTI). Film thickness was measured with a Tencor P-10 surface profilometer. Nonreducing SDS-PAGE and native PAGE were performed using NuPAGE 10% Bis-Tris gel and 10% Tris-glycine gels, respectively. Samples were diluted in LDS sample buffer for SDS-PAGE according to the manufacturer's instructions, heated to 90 °C for 2 min, and ran using MES SDS running buffer at 200 V for 35 min. For native PAGE, samples were diluted in native sample buffer without heating and ran under native running buffer at 75 V for 2.5 h. Finally, gels were stained with a silver staining kit (Pierce Biotechnology, Rockford, IL) according to the manufacturer's instructions.

In Vivo Murine Ear Skin Penetration. Animals were cared for in the USDA-inspected MIT Animal Facility under federal, state, local, and NIH guidelines for animal care. Tape-stripping was performed on wild-type C5BL/6J mice (Jackson Laboratories, Bar Harbor, ME) and MHC II-GFP mice (a gift from Professor Hidde Ploegh) immobilized under isoflurane anesthesia. Ears were hydrated briefly with PBS before being subjected to tape-stripping 10 times using cellophane adhesive tape (Office Depot invisible tape). Tape-stripped ears were subsequently swiped with PBS and pat dry before the application of LbL films (on their support-

ing substrates) onto the dorsal side. The application site was then sealed using Tegaderm and Nexcare medical tape (3M, Minneapolis, MN). Patches were kept on site for 2 days, following which mice were sacrificed and their ears excised. After removing the patches and rinsing with PBS, ears were split into dorsal and ventral halves. For wild-type mice, the cartilage-free dorsal halves were immunostained overnight with antimouse PE-I-A^b (MHC II) antibody (2 μ g/mL) to mark the LCs present. The stained ear sheet was then mounted on a glass slide, and 3D Z section images were obtained on a Zeiss LSM 510 confocal microscope using a 63 \times objective to visualize the penetration into skin. Relative fluorescence was determined by using Metamorph imaging software to compute the integrated intensity of images taken at each depth. Values obtained were then normalized by the maximum value measured in the entire stack of images; for the case of LC fluorescence, background signal was also subtracted prior to normalization. Histological sections of intact and tape-stripped mouse ears were prepared by fixing ears with formalin for 20 h and embedding in paraffin. Sections were sliced and stained with hemotoxylin and eosin.

Analysis of Cells in Auricular LNs. Auricular LNs recovered from mice were digested in a cocktail of Liberase Blendzyme 2 (Roche Applied Sciences, Indianapolis, IN) (0.28 WU/mL) and DNase I (Sigma, St. Louis, MO) (50 ng/mL) prepared in serum-free RPMI with gentle shaking for 1 h at ambient temperature. EDTA (5 mM) was added to quench enzymatic activity, and the suspension was allowed to settle for 10 min, following which the freed cells in suspension were aspirated from the remaining undigested tissue matrix. Recovered cells were rinsed once in PBS containing 1% BSA and EDTA (5 mM), then twice in PBS containing 1% BSA before resuspending them in flow cytometry buffer (1% BSA, 0.1% NaN₃ in Hank's balanced salt solution, pH 7.4) at 4 °C. The cells were blocked with anti-CD16/CD32 antibody (10 μ g/mL) for 10 min and then stained with fluorescent antibodies against surface markers for 20 min on ice, followed by three washes with flow cytometry buffer and addition of propidium iodide (PI) (1.25 μ g/mL) for viability assessment. Stained cells were analyzed on a BD FACSCalibur flow cytometer.

Acknowledgment. We thank E. Horrigan for help with animal studies. We thank the Center for Material Science and Engineering and Institute for Soldier Nanotechnologies for access to their characterization facilities. This work is supported by Institute for Soldier Nanotechnologies. X.S. acknowledges the financial support from the Agency for Science, Technology and Research, Singapore.

Supporting Information Available: Chemical structures of Poly-1 and Poly-2, ova loading at different pH values, nonreducing SDS-PAGE of ova released from films, and histology sections of tape-stripped murine ears. This material is available free of charge via the Internet at <http://pubs.acs.org>.

REFERENCES AND NOTES

- Decher, G. Fuzzy Nanoassemblies: Toward Layered Polymeric Multicomposites. *Science* **1997**, *277*, 1232–1237.
- Hammond, P. T. Form and Function in Multilayer Assembly: New Applications at the Nanoscale. *Adv. Mater.* **2004**, *16*, 1271–1293.
- Tang, Z. Y.; Wang, Y.; Podsiadlo, P.; Kotov, N. A. Biomedical Applications of Layer-by-Layer Assembly: From Biomimetics to Tissue Engineering. *Adv. Mater.* **2006**, *18*, 3203–3224.
- Jewell, C. M.; Lynn, D. M. Multilayered Polyelectrolyte Assemblies As Platforms for the Delivery of DNA and Other Nucleic Acid-Based Therapeutics. *Adv. Drug Delivery Rev.* **2008**, *60*, 979–999.
- Picart, C. Polyelectrolyte Multilayer Films: From Physico-Chemical Properties to the Control of Cellular Processes. *Curr. Med. Chem.* **2008**, *15*, 685–697.
- Wang, Y.; Angelatos, A. S.; Caruso, F. Template Synthesis of Nanostructured Materials via Layer-by-Layer Assembly. *Chem. Mater.* **2008**, *20*, 848–858.
- Lvov, Y.; Ariga, K.; Ichinose, I.; Kunitake, T. Assembly of Multicomponent Protein Films by Means of Electrostatic Layer-by-Layer Adsorption. *J. Am. Chem. Soc.* **1995**, *117*, 6117–6123.
- Lvov, Y.; Ariga, K.; Kunitake, T. Layer-by-Layer Assembly of Alternate Protein Polyion Ultrathin Films. *Chem. Lett.* **1994**, *12*, 2323–2326.
- Onda, M.; Lvov, Y.; Ariga, K.; Kunitake, T. Sequential Actions of Glucose Oxidase and Peroxidase in Molecular Films Assembled by Layer-by-Layer Alternate Adsorption. *Biotechnol. Bioeng.* **1996**, *51*, 163–167.
- Voegel, J. C.; Decher, G.; Schaaf, P. Polyelectrolyte Multilayer Films in the Biotechnology Field. *Actualite Chimique* **2003**, *11–12*, 30–38.
- Thompson, M. T.; Berg, M. C.; Tobias, I. S.; Rubner, M. F.; Van Vliet, K. J. Tuning Compliance of Nanoscale Polyelectrolyte Multilayers to Modulate Cell Adhesion. *Biomaterials* **2005**, *26*, 6836–6845.
- Elbert, D. L.; Herbert, C. B.; Hubbell, J. A. Thin Polymer Layers Formed by Polyelectrolyte Multilayer Techniques on Biological Surfaces. *Langmuir* **1999**, *15*, 5355–5362.
- Thierry, B.; Winnik, F. M.; Merhi, Y.; Tabrizian, M. Nanocoatings onto Arteries via Layer-by-Layer Deposition: Toward the *In Vivo* Repair of Damaged Blood Vessels. *J. Am. Chem. Soc.* **2003**, *125*, 7494–7495.
- Rajagopalan, P.; Shen, C. J.; Berthiaume, F.; Tilles, A. W.; Toner, M.; Yarmush, M. L. Polyelectrolyte Nano-scaffolds for the Design of Layered Cellular Architectures. *Tissue Eng.* **2006**, *12*, 1553–1563.
- Krol, S.; del Guerra, S.; Grupillo, M.; Diaspro, A.; Gliozzi, A.; Marchetti, P. Multilayer Nanoencapsulation. New Approach for Immune Protection of Human Pancreatic Islets. *Nano Lett.* **2006**, *6*, 1933–1939.
- Swiston, A. J.; Cheng, C.; Um, S. H.; Irvine, D. J.; Cohen, R. E.; Rubner, M. F. Surface Functionalization of Living Cells with Multilayer Patches. *Nano Lett.* **2008**, *8*, 4446–4453.
- Wilson, J. T.; Cui, W. X.; Chaikof, E. L. Layer-by-Layer Assembly of a Conformal Nanothin PEG Coating for Intraportal Islet Transplantation. *Nano Lett.* **2008**, *8*, 1940–1948.
- Wood, K. C.; Boedicker, J. Q.; Lynn, D. M.; Hammon, P. T. Tunable Drug Release from Hydrolytically Degradable Layer-by-Layer Thin Films. *Langmuir* **2005**, *21*, 1603–1609.
- Wood, K. C.; Chuang, H. F.; Batten, R. D.; Lynn, D. M.; Hammond, P. T. Controlling Interlayer Diffusion to Achieve Sustained, Multiagent Delivery from Layer-by-Layer Thin Films. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 10207–10212.
- Lynn, D. M. Peeling Back the Layers: Controlled Erosion and Triggered Disassembly of Multilayered Polyelectrolyte Thin Films. *Adv. Mater.* **2007**, *19*, 4118–4130.
- Macdonald, M.; Rodriguez, N. M.; Smith, R.; Hammond, P. T. Release of a Model Protein from Biodegradable Self Assembled Films for Surface Delivery Applications. *J. Controlled Release* **2008**, *131*, 228–234.
- Jewell, C. M.; Zhang, J. T.; Fredin, N. J.; Lynn, D. M. Multilayered Polyelectrolyte Films Promote the Direct and Localized Delivery of DNA to Cells. *J. Controlled Release* **2005**, *106*, 214–223.
- Jessel, N.; Oulad-Abdeighani, M.; Meyer, F.; Lavalle, P.; Haikel, Y.; Schaaf, P.; Voegel, J. C. Multiple and Time-Scheduled *In Situ* DNA Delivery Mediated by Beta-Cyclodextrin Embedded in a Polyelectrolyte Multilayer. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 8618–8621.
- Kim, B. S.; Park, S. W.; Hammond, P. T. Hydrogen-Bonding Layer-by-Layer Assembled Biodegradable Polymeric Micelles As Drug Delivery Vehicles from Surfaces. *ACS Nano* **2008**, *2*, 386–392.
- Caruso, F.; Mohwald, H. Protein Multilayer Formation on Colloids through a Stepwise Self-Assembly Technique. *J. Am. Chem. Soc.* **1999**, *121*, 6039–6046.
- Vazquez, E.; Dewitt, D. M.; Hammond, P. T.; Lynn, D. M. Construction of Hydrolytically-Degradable Thin Films via Layer-by-Layer Deposition of Degradable Polyelectrolytes. *J. Am. Chem. Soc.* **2002**, *124*, 13992–13993.
- Kim, B. S.; Smith, R. C.; Poon, Z. Y., *Langmuir* submitted.
- Kim, B. S.; Lee, H.; Min, Y. H.; Poon, Z.; Hammond, P. T. Hydrogen-Bonded Multilayer of pH-Responsive Polymeric Micelles with Tannic Acid for Surface Drug Delivery. *Chem. Commun.* **2009**, *28*, 4194–4196.
- Mitragotri, S. Immunization without Needles. *Nat. Rev. Immunol.* **2005**, *5*, 905–916.
- Prausnitz, M. R.; Langer, R. Transdermal Drug Delivery. *Nat. Biotechnol.* **2008**, *12*, 1261–1268.
- Babiuk, S.; Baca-Estrada, M.; Babiuk, L. A.; Ewen, C.; Foldvari, M. Cutaneous Vaccination: The Skin As an Immunologically Active Tissue and the Challenge of Antigen Delivery. *J. Controlled Release* **2000**, *66*, 199–214.
- Glenn, G. M.; Kenney, R. T.; Ellingsworth, L. R.; Frech, S. A.; Hammond, S. A.; Zoetewij, J. P. Transcutaneous Immunization and Immunostimulant Strategies: Capitalizing on the Immunocompetence of the Skin. *Exp. Rev. Vaccines* **2003**, *2*, 253–267.
- Warger, T.; Schild, H.; Rechtsteiner, G. Initiation of Adaptive Immune Responses by Transcutaneous Immunization. *Immunol. Lett.* **2007**, *109*, 13–20.
- Klimuk, S. K.; Najjar, H. M.; Semple, S. C.; Aslanian, S.; Dutz, J. P. Epicutaneous Application of CpG Oligodeoxynucleotides with Peptide or Protein Antigen Promotes the Generation of CTL. *J. Invest. Dermatol.* **2004**, *122*, 1042–1049.
- Inoue, J.; Yotsumoto, S.; Sakamoto, T.; Tsuchiya, S.; Aramaki, Y. Changes in Immune Responses to Antigen Applied to Tape-Stripped Skin with CpG-Oligodeoxynucleotide in Mice. *J. Controlled Release* **2005**, *108*, 294–305.
- Ishii, Y.; Nakae, T.; SakaMoto, F.; Matsuo, K.; Quan, Y. S.; Kamiyama, F.; Fujita, T.; Yamamoto, A.; Nakagawa, S.; Okada, N. A Transcutaneous Vaccination System Using a Hydrogel Patch for Viral and Bacterial Infection. *J. Controlled Release* **2008**, *131*, 113–120.
- Lynn, D. M.; Langer, R. Degradable Poly(beta-amino esters): Synthesis, Characterization, And Self-Assembly with Plasmid DNA. *J. Am. Chem. Soc.* **2000**, *122*, 10761–10768.
- Akinc, A.; Anderson, D. G.; Lynn, D. M.; Langer, R. Synthesis of Poly(beta-amino ester)s Optimized for Highly Effective Gene Delivery. *Bioconjugate Chem.* **2003**, *14*, 979–988.
- Murthy, N.; Xu, M. C.; Schuck, S.; Kunisawa, J.; Shastri, N.; Frechet, J. M. J. A Macromolecular Delivery Vehicle for Protein-Based Vaccines: Acid-Degradable Protein-Loaded Microgels. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 4995–5000.
- Bonifaz, L. C.; Bonnyay, D. P.; Charalambous, A.; Darguste, D. I.; Fujii, S. I.; Soares, H.; Brimnes, M. K.; Moltedo, B.; Moran, T. M.; Steinman, R. M. *In Vivo* Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination. *J. Exp. Med.* **2004**, *199*, 815–824.

41. Reddy, S. T.; van der Vlies, A. J.; Simeoni, E.; Angeli, V.; Randolph, G. J.; O'Neill, C. P.; Lee, L. K.; Swartz, M. A.; Hubbell, J. A. Exploiting Lymphatic Transport and Complement Activation in Nanoparticle Vaccines. *Nat. Biotechnol.* **2007**, *25*, 1159–1164.
42. Glenn, G. M.; Scharton-Kersten, T.; Vassell, R.; Matyas, G. R.; Alving, C. R. Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins As Antigenes and Adjuvants. *Infect. Immun.* **1999**, *67*, 1100–1106.
43. Scharton-Kersten, T.; Yu, J. M.; Vassell, R.; O'Hagan, D.; Alving, C. R.; Glenn, G. M. Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins, Subunits, And Unrelated Adjuvants. *Infect. Immun.* **2000**, *68*, 5306–5313.
44. Godefroy, S.; Peyre, A.; Garcia, N.; Muller, S.; Sesardic, D.; Partidos, C. D. Effect of Skin Barrier Disruption on Immune Responses to Topically Applied Cross-Reacting Material, CRM197 of Diphtheria Toxin. *Infect. Immun.* **2005**, *73*, 4803–4809.
45. Kahlon, R.; Hu, Y. X.; Orteu, C. H.; Kifayet, A.; Trudeau, J. D.; Tan, R. S.; Dutz, J. P. Optimization of Epicutaneous Immunization for the Induction of CTL. *Vaccine* **2003**, *21*, 2890–2899.
46. Strid, J.; Hourihane, J.; Kimber, I.; Callard, R.; Strobel, S. Disruption of the Stratum Corneum Allows Potent Epicutaneous Immunization with Protein Antigens Resulting in a Dominant Systemic Th2 Response. *Eur. J. Immunol.* **2004**, *34*, 2100–2109.
47. Bos, J. D.; Meinardi, M. The 500 Da Rule for the Skin Penetration of Chemical Compounds and Drugs. *Exp. Dermatol.* **2000**, *9*, 165–169.
48. Choi, M. J.; Maibach, H. I. Topical Vaccination of DNA Antigens: Topical Delivery of DNA Antigens. *Skin Pharmacol. Appl. Skin Physiol.* **2003**, *16*, 271–282.
49. Yagi, H.; Hashizume, H.; Horibe, T.; Yoshinari, Y.; Hata, M.; Ohshima, A.; Ito, T.; Takigawa, M.; Shibaki, A.; Shimizu, H.; Seo, N. Induction of Therapeutically Relevant Cytotoxic T Lymphocytes in Humans by Percutaneous Peptide Immunization. *Cancer Res.* **2006**, *66*, 10136–10144.
50. Vogt, A.; Mahe, B.; Costagliola, D.; Bonduelle, O.; Hadam, S.; Schaefer, G.; Schaefer, H.; Katlama, C.; Sterry, W.; Autran, B.; Blume-Peytavi, U.; Combadiere, B. Transcutaneous Anti-Influenza Vaccination Promotes Both CD4 and CD8 T Cell Immune Responses in Humans. *J. Immunol.* **2008**, *180*, 1482–1489.
51. Seo, N.; Tokura, Y.; Nishijima, T.; Hashizume, H.; Furukawa, F.; Takigawa, M. Percutaneous Peptide Immunization via Corneum Barrier-Disrupted Murine Skin for Experimental Tumor Immunoprophylaxis. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 371–376.
52. Nair, S.; McLaughlin, C.; Weizer, A.; Su, Z.; Boczkowski, D.; Dannull, J.; Vieweg, J.; Gilboa, E. Injection of Immature Dendritic Cells into Adjuvant-Treated Skin Obviates the Need for *Ex Vivo* Maturation. *J. Immunol.* **2003**, *171*, 6275–6282.
53. Larsen, C. P.; Steinman, R. M.; Witmerpack, M.; Hankins, D. F.; Morris, P. J.; Austyn, J. M. Migration and Maturation of Langerhans Cells in Skin Transplants and Explants. *J. Exp. Med.* **1990**, *172*, 1483–1493.
54. Stoitzner, P.; Holzmann, S.; McLellan, A. D.; Ivarsson, L.; Stossel, H.; Kapp, M.; Kammerer, U.; Douillard, P.; Kampgen, E.; Koch, F.; Saeland, S.; Romani, N. Visualization and Characterization of Migratory Langerhans Cells in Murine Skin and Lymph Nodes by Antibodies against Langerin/CD207. *J. Invest. Dermatol.* **2003**, *120*, 266–274.
55. Henri, S.; Vremec, D.; Kamath, A.; Waithman, J.; Williams, S.; Benoist, C.; Burnham, K.; Saeland, S.; Handman, E.; Shortman, K. The Dendritic Cell Populations of Mouse Lymph Nodes. *J. Immunol.* **2001**, *167*, 741–748.
56. Douillard, P.; Stoitzner, P.; Tripp, C. H.; Clair-Moninot, V.; Ait-Yahia, S.; McLellan, A. D.; Eggert, A.; Romani, N.; Saeland, S. Mouse Lymphoid Tissue Contains Distinct Subsets of Langerin/CD207+ Dendritic Cells, Only One of Which Represents Epidermal-Derived Langerhans Cells. *J. Invest. Dermatol.* **2005**, *125*, 983–994.
57. Weinlich, G.; Heine, M.; Stossel, H.; Zanella, M.; Stoitzner, P.; Ortner, U.; Smolle, J.; Koch, F.; Sepp, N. T.; Schuler, G.; Romani, N. Entry into Afferent Lymphatics and Maturation *In Situ* of Migrating Murine Cutaneous Dendritic Cells. *J. Invest. Dermatol.* **1998**, *110*, 441–448.
58. Wilson, N. S.; El-Sukkari, D.; Belz, G. T.; Smith, C. M.; Steptoe, R. J.; Heath, W. R.; Shortman, K.; Villadangos, J. A. Most Lymphoid Organ Dendritic Cell Types Are Phenotypically and Functionally Immature. *Blood* **2003**, *102*, 2187–2194.
59. Guy, B. the Perfect Mix: Recent Progress in Adjuvant Research. *Nat. Rev. Microbiol.* **2007**, *5*, 505–517.
60. Vollmer, J.; Krieg, A. M. Immunotherapeutic Applications of CpG Oligodeoxynucleotide TLR9 Agonists. *Adv. Drug Delivery Rev.* **2009**, *61*, 195–204.
61. Shortman, K.; Liu, Y. J. Mouse and Human Dendritic Cell Subtypes. *Nat. Rev. Immunol.* **2002**, *2*, 151–161.
62. Yang, Y. P.; Huang, C. T.; Huang, X. P.; Pardoll, D. M. Persistent Toll-like Receptor Signals Are Required for Reversal of Regulatory T Cell-Mediated CD8 Tolerance. *Nat. Immunol.* **2004**, *5*, 508–515.
63. Picart, C.; Mutterer, J.; Richert, L.; Luo, Y.; Prestwich, G. D.; Schaaf, P.; Voegel, J. C.; Lavalle, P. Molecular Basis for the Explanation of the Exponential Growth of Polyelectrolyte Multilayers. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, *99*, 12531–12535.
64. Zacharia, N. S.; DeLongchamp, D. M.; Modestino, M.; Hammond, P. T. Controlling Diffusion and Exchange in Layer-by-Layer Assemblies. *Macromolecules* **2007**, *40*, 1598–1603.
65. Kharlampieva, E.; Ankner, J. F.; Rubinstein, M.; Sukhishvili, S. A. pH-Induced Release of Polyanions from Multilayer Films. *Phys. Rev. Lett.* **2008**, *100*, 12.